Physician profile
Syed Asif Umar
NPI 1316043540
$6,963.49
in general payments reported to CMS, 2019-2025
25 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $663 · 2021: $972 · 2022: $958 · 2023: $1,346 · 2024: $1,068 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,128.54 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $965.25 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $811.68 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $689.90 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $516.84 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $444.55 | 2021-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $382.88 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $380.39 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $263.87 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.77 | 2020-2025 | Caplyta |
| Allergan, INC. | $244.94 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $175.51 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $151.95 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $126.42 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $125.37 | 2021-2025 | Uzedy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $72.79 | 2023-2024 | Quviviq |
| Indivior INC. | $43.30 | 2022 | |
| Eisai INC. | $38.69 | 2021 | |
| Neurocrine Biosciences, INC. | $30.73 | 2020-2023 | Ingrezza |
| Merck Sharp & Dohme LLC | $30.10 | 2020-2021 | |
| Neuronetics, INC. | $22.19 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $14.45 | 2021 | |
| Bausch Health US, LLC | $14.40 | 2020 | |
| Acadia Pharmaceuticals INC | $14.29 | 2021 | |
| Owp Pharmaceuticals, INC. | $13.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Umar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.